These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2169779)

  • 1. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group.
    Soukop M
    Eur J Cancer; 1990; 26 Suppl 1():S15-9. PubMed ID: 2169779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group.
    Smith IE
    Eur J Cancer; 1990; 26 Suppl 1():S19-23. PubMed ID: 2169780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis.
    Cupissol DR; Serrou B; Caubel M
    Eur J Cancer; 1990; 26 Suppl 1():S23-7. PubMed ID: 2169782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group.
    Chevallier B
    Eur J Cancer; 1990; 26 Suppl 1():S33-6. PubMed ID: 2169784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
    Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
    Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group.
    Marty M
    Eur J Cancer; 1990; 26 Suppl 1():S28-32. PubMed ID: 2169783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of the antiemetic effectiveness of granisetron and alizapride plus dexamethasone in cytostatic therapy].
    Bremer K; Uhlenbusch R
    Dtsch Med Wochenschr; 1991 Nov; 116(48):1817-23. PubMed ID: 1659980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
    Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
    Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group.
    Soukop M
    Support Care Cancer; 1994 May; 2(3):177-83. PubMed ID: 8032704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
    Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
    Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
    Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
    Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation.
    Spitzer TR; Friedman CJ; Bushnell W; Frankel SR; Raschko J
    Bone Marrow Transplant; 2000 Jul; 26(2):203-10. PubMed ID: 10918432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
    Hesketh PJ; Gandara DR; Hesketh AM; Edelman M; Webber LM; McManus M; Hainsworth JD
    Cancer J Sci Am; 1997; 3(3):180-3. PubMed ID: 9161784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in Cisplatin-based chemotherapy: a randomized controlled trial.
    Cheirsilpa A; Sinthusake T; Songsakkaesorn A; Visawaprasit S; Chulaka K; Changkuingdee N
    Jpn J Clin Oncol; 2005 Dec; 35(12):695-9. PubMed ID: 16319109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
    Navari RM; Kaplan HG; Gralla RJ; Grunberg SM; Palmer R; Fitts D
    J Clin Oncol; 1994 Oct; 12(10):2204-10. PubMed ID: 7931490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of granisetron for nausea and vomiting induced by anticancer drugs--multi-centered placebo-controlled double-blind comparative study].
    Suminaga M; Furue H; Ohta K; Taguchi T; Niitani H; Ogawa N
    Gan To Kagaku Ryoho; 1993 Jul; 20(9):1211-9. PubMed ID: 8392826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of granisetron alone and granisetron plus hydroxyzine hydrochloride for the prophylactic treatment of emesis induced by cisplatin-containing chemotherapy].
    Tsukuda M; Kokatsu T; Furukawa S; Kohno H; Kubota A; Furukawa M; Enomoto H
    Gan To Kagaku Ryoho; 1993 Oct; 20(13):2037-41. PubMed ID: 8215478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical evaluation of granisetron for nausea and vomiting induced by anticancer drugs--optimal dose-finding study].
    Suminaga M; Furue H; Ohta K; Taguchi T; Niitani H; Ogawa N
    Gan To Kagaku Ryoho; 1993 Jul; 20(9):1203-10. PubMed ID: 8392825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy.
    Tabona MV
    Eur J Cancer; 1990; 26 Suppl 1():S37-44. PubMed ID: 2169785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.